US EditionAlzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study
- Alzheon announced on Thursday that valiltramiprosate, their Alzheimer's pill, failed to meet its primary goal in a Phase 3 clinical trial.
- Alzheon designed the therapy to reduce amyloid plaque, a hallmark of Alzheimer's, but it has a history of trial shortfalls.
- The APOLLOE4 study enrolled 325 patients with early Alzheimer's who were homozygous for the APOE4 allele.
- Susan Abushakra, Alzheon's chief medical officer, stated that a "precision medicine approach is key" for APOE4/4 patients.
- Despite missing the primary endpoint, Alzheon continues a long-term extension study, seeing potential in a pre-specified group with early-stage disease.
6 Articles
6 Articles
Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study
Alzheon hoped testing its drug in a genetically defined subgroup of Alzheimer’s disease patients would succeed, overcoming earlier clinical trial failures. Instead, preliminary results show the pill failed to outdistance a placebo. The post Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study appeared first on MedCity News.
FASEB BioAdvances April 2025 Issue: Exploring the Intersection of Environmental Factors, Innovative Treatments, and Precision Medicine
The April 2025 issue of FASEB BioAdvances delves into the effects of global warming on obesity, innovative treatments for hypertension and kidney injury, gene recombination in neural tissues, and the future of precision medicine through AI and biomedical informatics.
ALS drug effectively treats Alzheimer’s disease in new animal study - Les Turner ALS Foundation
Experimental drug NU-9 — a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) — improves neuron health in animal models of Alzheimer’s disease, according to ... Read More The post ALS drug effectively treats Alzheimer’s disease in new animal study appeared first on Les Turner ALS Foundation.
Light beam will ‘grasp and hold’ single proteins linked to Alzheimer’s to reveal new insight into disease - Digital Health Technology News
High concentrations of light will be used to study the fast structural changes in single proteins linked to Alzheimer’s through the different disease stages in a first of its kind study. It is hoped the research, led by Nottingham Trent University, will provide fresh insight into the emergence and progression of neurodegenerative disease, which is known to begin up to 20 years before symptoms appear. Understanding these processes could pave the …
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
